Blood-based tau phosphorylated at threonine 217 (pTau217), for example, has been shown to distinguish amyloid-positive from amyloid-negative individuals [24], while transcranial magnetic stimulation (TMS) paradigms have detected cholinergic dysfunction associated with AD-related mild cognitive impairment [25]. Here, MAPT is linked to amyloidosis.